News
CUE
--
0.00%
--
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today that it will ta...
GlobeNewswire · 09/09 12:00
Is Cue Biopharma, Inc. (NASDAQ:CUE) Popular Amongst Insiders?
A look at the shareholders of Cue Biopharma, Inc. ( NASDAQ:CUE ) can tell us which group is most powerful. Institutions...
Simply Wall St. · 08/23 11:04
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
BRIEF-Cue Biopharma Inc Posts Qtrly Collaboration Revenue $2.7 Million Versus $1.1 Million
reuters.com · 08/17 20:48
Cue Biopharma Q2 EPS $(0.33) Beats $(0.42) Estimate, Sales $2.74M Beat $1.06M Estimate
Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.42) by 21.43 percent. This is a 13.16 percent increase over losses of $(0.38) per share from the
Benzinga · 08/17 20:03
Cue Biopharma Q2 Loss Narrows on Higher Revenue
MT Newswires · 08/17 16:21
Cue Biopharma to Host Business Update Call and Webcast
Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today it will host a ...
GlobeNewswire · 08/10 12:00
Cue Biopharma to Host Business Update Call and Webcast
CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within...
GlobeNewswire · 08/10 12:00
Cue Biopharma to Present Corporate Update at the Upcoming BTIG Virtual Biotechnology Conference
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today that it will pa...
GlobeNewswire · 08/03 12:00
Earnings Preview: Cue Biopharma, Inc. (CUE) Q2 Earnings Expected to Decline
Zacks.com · 07/30 19:00
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15)
Benzinga · 07/16 11:37
The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13)
Benzinga · 07/14 11:48
Stocks That Hit 52-Week Lows On Tuesday
    Before 10 a.m. ET on Tuesday, 48 companies set new 52-week lows.
Benzinga · 07/13 15:40
Cue Biopharma doses first patient in trial for CUE-101 in head and neck cancer
Chinnapong/iStock via Getty Images Massachusetts-based clinical-stage Cue Biopharma (CUE) announced the dosing of the first patient in Part B expansion phase of its Phase 1 study for CUE-101 as monotherapy at the
Seekingalpha · 06/10 12:38
BRIEF-Cue Biopharma Announces First Patient Dosed In Part B Patient Expansion Of Cue-101 Phase 1 Monotherapy Trial In Hpv+ Second Line And Beyond Hnscc
reuters.com · 06/10 12:14
Cue Biopharma's (NASDAQ:CUE) Stock Price Has Reduced 53% In The Past Year
Cue Biopharma, Inc. ( NASDAQ:CUE ) shareholders should be happy to see the share price up 15% in the last month. But...
Simply Wall St. · 05/24 06:18
Cue Biopharma Posts Narrower Q1 Loss, Higher Revenue
MT Newswires · 05/18 06:30
BRIEF-Cue Biopharma Posts Quarterly Loss Per Share Of $0.41
reuters.com · 05/17 20:49
Cue Biopharma EPS misses by $0.02, beats on revenue
Cue Biopharma (CUE): Q1 GAAP EPS of -$0.41 misses by $0.02.Revenue of $1.55M (+72.2% Y/Y) beats by $0.94M.“We finished the first quarter of 2021 in a solid financial position which
Seekingalpha · 05/17 20:20
Earnings Scheduled For May 17, 2021
  Companies Reporting Before The Bell • Hycroft Mining Holding (NASDAQ:HYMC) is estimated to report earnings for its first quarter.
Benzinga · 05/17 08:10
Webull provides a variety of real-time CUE stock news. You can receive the latest news about Cue Biopharma through multiple platforms. This information may help you make smarter investment decisions.
About CUE
Cue Biopharma Inc is a development-stage immunotherapy company. The Company is focused at developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease. Its Immuno-Oncology pipeline includes CUE-100 Framework, and CUE-200 Framework; and autoimmune pipeline includes MHC Class I Program, and MHC Class II Program. The CUE-100 Framework restricts the activity of T cell populations. The CUE-200 Framework enables potent, long-lived anti-tumor T cell responses. The Autoimmune disease therapy protects the healthy cells from immune attack.